RECOMBINANT HUMAN ENDOSTATIN MARKET ANALYSIS

Recombinant Human Endostatin Market, by Application (Medical Application, Scientific Application), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2262
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Key players operating in the global recombinant human endostatin market include, Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG.